| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17156 R71954 |
Vaclavik - Beta-blockers, 2024 | Low birth weight | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 2.54 [2.34;2.75] | -/676 -/66,393 | - | 676 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13995 R54973 |
Baard - Beta-blockers, 2020 | Low birth weight (< 2 500 g) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 1.01 [0.43;2.35] C | 9/43 28/135 | 37 | 43 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13509 R52191 |
Fitton - Beta-blockers (Controls unexposed, disease free), 2020 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified |
2.46 [1.75;3.45] excluded (control group) |
134/985 11,051/250,693 | 11,185 | 985 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14420 R57247 |
Fitton - Beta-blockers (Controls unexposed, sick), 2020 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.42 [1.16;1.72] C | 134/985 797/7,971 | 931 | 985 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13902 R54399 |
Duan - Beta-blockers, 2018 | Low birth weight (birth weight <2500g) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 4.91 [4.58;5.27] C | 1,025/4,847 19,393/374,391 | 20,418 | 4,847 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13891 R54555 |
Ishibashi - Beta-blockers, 2017 | Low birthweight infants (birth weight less than 2500 kg) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 3.25 [1.17;9.09] | 15/38 14/87 | 29 | 38 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13480 R52000 |
Orbach - Atenolol, 2013 | Low birthweight (< 2500 g) | 3rd trimester | retrospective cohort (claims database) | unexposed, disease free | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 3.89 [2.42;6.25] | 25/107 10,001/97,820 | 10,026 | 107 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13448 R51808 |
Su - Beta-blockers (Controls unexposed, disease free), 2013 | Low birth weight (< 2,500 gm) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
2.67 [1.96;3.63] C excluded (control group) |
52/414 418/8,181 | 470 | 414 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13442 R51790 |
Su - Beta-blockers (Controls unexposed, sick) , 2013 | Low birth weight (< 2,500 gm) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 1.70 [1.17;2.48] | 52/414 76/1,006 | 128 | 414 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14027 R55128 |
Rosenfeld - Pindolol, 1986 | Low birth weight (< 2500 g) | during pregnancy (anytime or not specified) | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified | 0.93 [0.28;3.06] C | 9/23 9/22 | 18 | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 8 studies | 2.24 [1.48;3.40] | 31,587 | 7,133 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick;
Asymetry test p-value = 0.2986 (by Egger's regression)
slope=1.3931 (0.2135); intercept=-3.3476 (2.9424); t=1.1377; p=0.2986
excluded 13448, 13509